142 results
Page 3 of 8
8-K
EX-99.1
mudtypw f33c90tw
15 Oct 20
Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial
4:47pm
8-K
EX-99.1
vh7leozv50vdz
28 Aug 20
Regulation FD Disclosure
10:44am
S-3ASR
vnnveqm
10 Aug 20
Automatic shelf registration
5:01pm
424B5
jvpon6x
2 Jun 20
Prospectus supplement for primary offering
5:05pm
424B5
4u614gx
1 Jun 20
Prospectus supplement for primary offering
6:06am
8-K
EX-99.1
cr1 9tbb13f8y2xrst
29 May 20
Regulation FD Disclosure
7:42am
8-K
EX-99.1
pdh0w1 ize1l0fu
14 May 20
Adaptimmune Reports Q1 Financial Results
7:37am
8-K
46j2rfldxlm
29 Apr 20
Other Events
8:06am
8-K
EX-99.1
4uqnzxr1x3p0309
29 Apr 20
Other Events
8:06am
8-K
EX-99.1
cz2ei2
27 Feb 20
Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update
7:39am
424B5
w9my9067rafjuop5
22 Jan 20
Prospectus supplement for primary offering
5:31pm
424B5
riuq3kqy6hxanq 6iui7
21 Jan 20
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
v44folyjjt5m
13 Jan 20
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
8:42am